Mauro Antimi

988 total citations
24 papers, 601 citations indexed

About

Mauro Antimi is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mauro Antimi has authored 24 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mauro Antimi's work include Bladder and Urothelial Cancer Treatments (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (4 papers). Mauro Antimi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (4 papers). Mauro Antimi collaborates with scholars based in Italy, France and India. Mauro Antimi's co-authors include Vito Lorusso, Cesare Gridelli, M. De Lena, Michael Pacini, Cristina Oliva, G Luporini, Giovanni Luca Frassineti, C. F. Pollera, Enrico Cortesi and Diana Giannarelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Mauro Antimi

23 papers receiving 583 citations

Peers

Mauro Antimi

SURGE

ONCOL

PRM

CR

MB

C. Bokemeyer Germany

Francis Navarro France

Omar Alhalabi United States

Kian Fong Foo Singapore

Yasuaki Kuwata Japan

Yuji Nukui Japan

Toshiki Kamano Japan

Zheng Tang China

Nicola Borsellino Italy

Toshiro Ogata Japan

C. Bokemeyer Germany

Mauro Antimi

258 ×0.9

SURGE

268 ×1.0

ONCOL

299 ×1.9

PRM

75 ×0.9

CR

171 ×2.1

MB

Citations per year, relative to Mauro Antimi Mauro Antimi (= 1×) peers C. Bokemeyer

Countries citing papers authored by Mauro Antimi

Since Specialization

Citations

This map shows the geographic impact of Mauro Antimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauro Antimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauro Antimi more than expected).

Fields of papers citing papers by Mauro Antimi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauro Antimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauro Antimi. The network helps show where Mauro Antimi may publish in the future.

Co-authorship network of co-authors of Mauro Antimi

This figure shows the co-authorship network connecting the top 25 collaborators of Mauro Antimi. A scholar is included among the top collaborators of Mauro Antimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauro Antimi. Mauro Antimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Lalle, Maurizio, et al.. (2009). Cellular and humoral immune alterations in thymectomized patients for thymoma. Annals of Hematology. 88(9). 847–853. 3 indexed citations

2.

Lalle, Maurizio, et al.. (2009). [Medical treatment for thymoma: an update].. PubMed. 159(2). 91–5.

3.

Papaldo, Paola, G. Ferretti, Serena Di Cosimo, et al.. (2006). Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?. Journal of Clinical Oncology. 24(19). 3048–3055. 27 indexed citations

4.

Lalle, Maurizio, et al.. (2005). Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.. PubMed. 24(2). 197–201. 4 indexed citations

5.

Papaldo, Paola, Massimo Lopez, Paolo Marolla, et al.. (2005). Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. Journal of Clinical Oncology. 23(28). 6908–6918. 74 indexed citations

6.

Lalle, Maurizio, Luca De Rosa, A Perillo, et al.. (2005). [High-dose chemotherapy for metastatic breast cancer].. PubMed. 155(7-8). 305–15. 1 indexed citations

7.

Ceribelli, Anna, Cesare Gridelli, Filippo de Marinis, et al.. (2003). Prolonged gemcitabine infusion in advanced non–small cell lung carcinoma. Cancer. 98(2). 337–343. 40 indexed citations

8.

Lorusso, Vito, Luigi Manzione, Ferdinando De Vita, et al.. (2000). GEMCITABINE PLUS CISPLATIN FOR ADVANCED TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT: A PHASE II MULTICENTER TRIAL. The Journal of Urology. 53–56. 1 indexed citations

9.

Michetti, Murielle, et al.. (2000). [A case of primary non-Hodgkin lymphoma of the breast].. PubMed. 150(4). 307–10. 1 indexed citations

10.

Lorusso, Vito, Luigi Manzione, Ferdinando De Vita, et al.. (2000). GEMCITABINE PLUS CISPLATIN FOR ADVANCED TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT: A PHASE II MULTICENTER TRIAL. The Journal of Urology. 164(1). 53–56. 35 indexed citations

11.

Milella, Michele Stanislaw, Cecilia Nisticò, Virginia Ferraresi, et al.. (1999). Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women. Breast Cancer Research and Treatment. 55(3). 259–266. 16 indexed citations

12.

Mancarella, S., Vito Lorusso, Luigi Manzione, et al.. (1999). Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial. European Journal of Cancer. 35. S347–S348. 3 indexed citations

13.

Porta, Adriana, et al.. (1999). [Metaplastic tumors of the breast: a case of primary squamous cell carcinoma].. PubMed. 150(2). 153–7. 2 indexed citations

14.

Lorusso, Vito, C. F. Pollera, Mauro Antimi, et al.. (1998). A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. European Journal of Cancer. 34(8). 1208–1212. 242 indexed citations

15.

Cui, Ning‐hua, et al.. (1998). Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anti-Cancer Drugs. 9(5). 387–392. 14 indexed citations

16.

Palumbo, Raffaella, Sebastian T. Palmeri, Mauro Antimi, et al.. (1997). Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Annals of Oncology. 8(11). 1159–1162. 51 indexed citations

17.

Antimi, Mauro, et al.. (1993). A Phase I Safety Study of Doxifluridine and Interferon-α-2a in Patients with Advanced Neoplastic Disease. Tumori Journal. 79(5). 336–339. 1 indexed citations

18.

Antimi, Mauro, M Masi, André Delannoy, et al.. (1991). The plicamycin and hydroxyurea combination chemotherapy for chronic granulocytic leukemia in myeloid transformation.. PubMed. 75(5). 443–6. 1 indexed citations

19.

Iudicone, Paola, Enrico Girardi, Mauro Antimi, et al.. (1989). Functional analysis of lymphocytes from two patients affected by common variable immunodeficiency (CVI).. PubMed. 74(4). 359–63. 3 indexed citations

20.

Giampaolo, Adele, Giovanni Di Salvo, P Cianciulli, et al.. (1982). Hb Belfast (beta 15 (A 12) Trp leads to Arg) in combination with G6PD deficiency in an Italian carrier.. PubMed. 67(3). 335–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact